Gheidari Fatemeh, Arefian Ehsan, Jamshidi Adegani Fatemeh, Fallah Atanaki Fereshteh, Soleimani Masoud
Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran.
Stem Cell Technology Research Center, Tehran, Iran.
Iran J Pharm Res. 2021 Fall;20(4):202-212. doi: 10.22037/ijpr.2021.115089.15193.
Glioblastoma is the most lethal malignancy of the brain and is resistant to conventional cancer treatments. Gene-therapy approaches like using tumor suppressor miRNAs are promising in the treatment of glioblastoma. They control the expression of oncogenes and influence tumor features and behaviors. Therefore, in the present study, it was predicted that miR-142 regulates oncogenic epidermal growth factor receptor () signaling pathway via TargetScan and miRWalk online tools. Its differential expression level was reduced in glioblastoma according to the previous microarray results, and its predicted target genes were upregulated, as shown by the Expression Atlas. The miR-142 was overexpressed in U-87 glioblastoma cells via lentiviral transduction, and the way it influences proliferation and migration of cells was investigated through MTT assay and wound healing assay. Apoptosis rate was also measured via the Annexin V assay, and cell-cycle analysis was done. Then, real-time polymerase chain reaction (real-time PCR) and western blotting were performed to assess fold changes in mRNA and protein levels of the miR-142 predicted targets. Direct target genes of miR-142 were confirmed through a dual-luciferase reporter assay. The miR-142 significantly suppressed cell proliferation and migration and induced apoptosis and cell-cycle arrest in U-87 glioblastoma cells. This was accompanied by a decrease in expression of SHC adaptor protein 4 (), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (), v-akt murine thymoma viral oncogene homolog 1 (), Kirsten rat sarcoma viral oncogene homolog (), and mitogen-activated protein kinase 8 () oncogenes at mRNA and protein levels in glioblastoma cells. Also, was demonstrated as a direct target of miR-142. Overall, miR-424 acts as tumor suppressor miRNA in glioblastoma cells.
胶质母细胞瘤是最致命的脑恶性肿瘤,对传统癌症治疗具有抗性。诸如使用肿瘤抑制性微小RNA(miRNA)的基因治疗方法在胶质母细胞瘤治疗中具有前景。它们控制癌基因的表达并影响肿瘤特征和行为。因此,在本研究中,通过TargetScan和miRWalk在线工具预测miR-142调节致癌性表皮生长因子受体()信号通路。根据先前的微阵列结果,其在胶质母细胞瘤中的差异表达水平降低,并且如表达图谱所示,其预测的靶基因上调。通过慢病毒转导在U-87胶质母细胞瘤细胞中过表达miR-142,并通过MTT试验和伤口愈合试验研究其影响细胞增殖和迁移的方式。还通过膜联蛋白V试验测量凋亡率,并进行细胞周期分析。然后,进行实时聚合酶链反应(实时PCR)和蛋白质印迹以评估miR-142预测靶标的mRNA和蛋白质水平的倍数变化。通过双荧光素酶报告基因试验证实miR-142的直接靶基因。miR-142显著抑制U-87胶质母细胞瘤细胞的增殖和迁移,并诱导凋亡和细胞周期停滞。这伴随着胶质母细胞瘤细胞中SHC衔接蛋白4()、磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α()、v-akt小鼠胸腺瘤病毒癌基因同源物1()、 Kirsten大鼠肉瘤病毒癌基因同源物()和丝裂原活化蛋白激酶8()癌基因在mRNA和蛋白质水平的表达降低。此外, 被证明是miR-142的直接靶标。总体而言,miR-424在胶质母细胞瘤细胞中作为肿瘤抑制性miRNA发挥作用。